The Association Between Tacrolimus Levels and Hyperkalemia in Allograft Recipients Who Underwent Heart or Lung Transplantation in New Orleans, USA Between 2013 and 2019: A Single-Center Retrospective Study

Overview

Journal Ann Transplant

Specialty General Surgery

Date 2022 Aug 2

PMID 35915576

Authors

Olivia L Griffis

Steven Q Thai

Cody Allison

Brooke Baetz

Alaa Mohammed

Affiliations

Soon will be listed here.

Abstract

BACKGROUND Tacrolimus, a calcineurin inhibitor, is the cornerstone of immunosuppressive strategies in transplantation. Other studies have concluded that hyperkalemia correlates with tacrolimus therapy, though the impact is poorly understood. In 2 separate analyses, the aim of this study was to investigate if the presence and/or magnitude of exposure to tacrolimus increased potassium levels in heart or lung transplant recipients. MATERIAL AND METHODS This retrospective study identified allograft recipients who underwent heart or lung transplantation from January 2013 to December 2019 at Ochsner Health in New Orleans, USA. The first analysis (A-1) comprised 103 lung transplant patients' assessed potassium levels and prevalence of hyperkalemia in the absence of tacrolimus before transplant versus 30 days after transplant on tacrolimus. The second analysis (A-2) included 187 heart or lung transplant recipients and compared potassium levels and prevalence of hyperkalemia at day 30 after transplant during higher tacrolimus exposure (High-TAC) vs day 300 during lower tacrolimus exposure (Low-TAC). RESULTS In A-1, patients on tacrolimus had higher median potassium (4.7 mmol/L vs 4.1 mmol/L, P<0.0001) and prevalence of hyperkalemia (32.04% vs 5.83%, P<0.0001). In A-2, patients in the High-TAC group had higher median potassium (4.6 mmol/L vs 4.4 mmol/L, P=0.0005) and prevalence of hyperkalemia (22.46% vs 12.30%, P=0.0056). CONCLUSIONS Our findings support those from previous studies. Presence of and higher levels of tacrolimus were associated with hyperkalemia following heart and lung transplantation. These findings highlight the importance of long-term monitoring of potassium levels in patients treated with tacrolimus.

References

Heering P, Kurschat C, Vo D, Klein-Vehne N, Fehsel K, Ivens K . Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression. Clin Transplant. 2004; 18(2):186-92. DOI: 10.1046/j.1399-0012.2003.00154.x. View

Chambers D, Cherikh W, Harhay M, Hayes Jr D, Hsich E, Khush K . The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019; 38(10):1042-1055. PMC: 6816340. DOI: 10.1016/j.healun.2019.08.001. View

Costanzo M, Dipchand A, Starling R, Anderson A, Chan M, Desai S . The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010; 29(8):914-56. DOI: 10.1016/j.healun.2010.05.034. View

Uriel M, Holzhauser L, Nguyen A, Imamura T, Lourenco L, Rodgers D . Incidence and Clinical Significance of Hyperkalemia Following Heart Transplantation. Transplant Proc. 2020; 53(2):673-680. DOI: 10.1016/j.transproceed.2020.11.002. View

Whalen H, Glen J, Harkins V, Stevens K, Jardine A, Geddes C . High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. Transplantation. 2016; 101(2):430-436. DOI: 10.1097/TP.0000000000001129. View

Singh J, Kichloo A, Vipparla N, Aljadah M, Albosta M, Jamal S . Hyperkalemia: Major but still understudied complication among heart transplant recipients. World J Transplant. 2021; 11(6):203-211. PMC: 8218349. DOI: 10.5500/wjt.v11.i6.203. View

Hoorn E, Walsh S, McCormick J, Furstenberg A, Yang C, Roeschel T . The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011; 17(10):1304-9. PMC: 3192268. DOI: 10.1038/nm.2497. View

Ribeiro H, Oliveira M, Anastacio L, Generoso S, Lima A, Correia M . PREVALENCE AND RISK FACTORS OF HYPERKALEMIA AFTER LIVER TRANSPLANTATION. Arq Bras Cir Dig. 2018; 31(1):e1357. PMC: 6050000. DOI: 10.1590/0102-672020180001e1357. View

Gullestad L, Iversen M, Mortensen S, Eiskjaer H, Riise G, Mared L . Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation. 2010; 89(7):864-72. DOI: 10.1097/TP.0b013e3181cbac2d. View

10.

Kobashigawa J . Clinical trials in heart transplantation: The evolution of evidence in immunosuppression. J Heart Lung Transplant. 2017; 36(12):1286-1290. DOI: 10.1016/j.healun.2017.10.009. View

11.

McDermott J, Girgis R . Individualizing immunosuppression in lung transplantation. Glob Cardiol Sci Pract. 2018; 2018(1):5. PMC: 5857067. DOI: 10.21542/gcsp.2018.5. View

12.

Higgins R, Ramaiyan K, Dasgupta T, Kanji H, Fletcher S, Lam F . Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. Nephrol Dial Transplant. 2004; 19(2):444-50. DOI: 10.1093/ndt/gfg515. View

13.

Khush K, Cherikh W, Chambers D, Harhay M, Hayes Jr D, Hsich E . The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019; 38(10):1056-1066. PMC: 6816343. DOI: 10.1016/j.healun.2019.08.004. View

14.

Trofe-Clark J, Brennan D, West-Thielke P, Milone M, Lim M, Neubauer R . Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. Am J Kidney Dis. 2017; 71(3):315-326. DOI: 10.1053/j.ajkd.2017.07.018. View

15.

Rizk J, Quan D, Gabardi S, Rizk Y, Kalantar-Zadeh K . Novel approaches to management of hyperkalaemia in kidney transplantation. Curr Opin Nephrol Hypertens. 2020; 30(1):27-37. DOI: 10.1097/MNH.0000000000000657. View

16.

Sahu M, Singh S, Das A, Abraham A, Airan B, Alam I . High blood tacrolimus and hyperkalemia in a heart transplant patient. Ann Card Anaesth. 2017; 20(2):270-271. PMC: 5408543. DOI: 10.4103/0971-9784.203933. View

17.

Ensor C, Iasella C, Harrigan K, Morrell M, Moore C, Shigemura N . Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018; 18(6):1527-1533. DOI: 10.1111/ajt.14723. View

18.

Brunet M, van Gelder T, Asberg A, Haufroid V, Hesselink D, Langman L . Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther Drug Monit. 2019; 41(3):261-307. DOI: 10.1097/FTD.0000000000000640. View